Community Approach Targeting Cirrhosis and Hepatocellular Carcinoma (CATCH) - Community Cirrhosis Prevalence in Viral Hepatitis
AASLD LiverLearning®, Stephen Bloom, 144640
Early Hospital Readmissions and Mortality in Patients with Decompensated Cirrhosis enrolled in a Large National Health Insurance Administrative Database
AASLD LiverLearning®, Steven Scaglione, 144641
Efficacy and safety of sofosbuvir-based therapy for aged patients with chronic hepatitis C
AASLD LiverLearning®, Ayako Urabe, 144897
Predictors Of 30-Day Readmission In Patients Hospitalized With Decompensated Cirrhosis in a Large State Based Inpatient Sample
AASLD LiverLearning®, Sehem Ghazala, 144642
Efficacy and safety of paritaprevir/ritonavir, ombitasvir and dasabuvir + ribavirin for treatment of HCV genotype 1b compensated cirrhosis in patients aged 65 years or older
AASLD LiverLearning®, Anca Trifan, 144898
Efficacy and safety of ombitasvir (OBV) and ritonavir boosted paritaprevir (PRV/r) with or without dasabuvir (DSV) regimens in genotype 1 or 4 HCV infected patients. A Greek multicenter real-life cohort study.
AASLD LiverLearning®, IOANNIS VLACHOGIANNAKOS, 144899
Effect and safety of daclatasvir and asunaprevir combination therapy for chronic hepatitis or compensated cirrhosis by HCV genotype 1b infection in patients with renal dysfunction; From real world data.
AASLD LiverLearning®, Masatoshi Ishigami, 144900
Hospitalist-based Healthcare Delivery Model in Cirrhosis - A Comparative Effectiveness Study in Management of Upper Gastrointestinal Bleeding
AASLD LiverLearning®, Kai Rou Tey, 144656
A Creatinine-Modified Child-Turcotte-Pugh (CTP-Cr) outperforms the original CTP and Model for End Stage Liver Disease (MELD) for predicting short- and long-term transplant-free survival in a national cohort with cirrhosis.
AASLD LiverLearning®, David Kaplan, 144657
Virological Response rates using Generic Direct Acting Antiviral Treatment for Hepatitis C, Legally Imported into Russia
AASLD LiverLearning®, Julia Dragunova, 144913
Hepatitis A and B vaccination rates in patients with chronic liver disease: A Quality Improvement Project
AASLD LiverLearning®, Moaz Sial, 144658
Changes in Liver Stiffness and Clinical Outcomes after SVR in Patients with Advanced Fibrosis or Cirrhosis from Hepatitis C Virus
AASLD LiverLearning®, Sonal Kumar, 144914
Ledipasvir/sofosbuvir is effective and well tolerated in post-kidney transplant patients with chronic hepatitis C virus.
AASLD LiverLearning®, Amilcar Morales-Cardona, 144915
Effect of Ethnicity on HCV Patient Outcomes and Access to Therapy in Era of All DAA Regimens: Real-World Experience From the Trio Network
AASLD LiverLearning®, Kevin Korenblat, 144916
Peak Immunogenicity of Two Doses of Investigational HEPLISAV-B™ in Difficult to Vaccinate Individuals: Seroprotection Rates in Three Phase 3 Trials
AASLD LiverLearning®, Sam Jackson, 144672
Racial disparity in the Prevalence of Hepatitis B Virus (HBV) Immunity in the United States: Results from the National Health and Nutrition Examination Survey 2011-2014
AASLD LiverLearning®, Hyunseok Kim, 144673
Predictors of mortality in patients hospitalized with spontaneous bacterial peritonitis: Analysis of National Inpatient Sample, 2009-2011
AASLD LiverLearning®, Bryan Love, 144929
Low Rates of Hepatitis B Virus (HBV) Screening and Low Rates of HBV Awareness Among High Risk Patients at a Large, Urban, Safety-Net Hospital
AASLD LiverLearning®, Robert Wong, 144674
ATTIRE Stage 1 - Albumin To prevenT Infection in chronic liveR failurE : a single-arm feasibility trial of targeted therapy with 20% Human Albumin Solution
AASLD LiverLearning®, Louise China, 144930
Increased risk of in-hospital sepsis related mortality and non-ICU death in patients with cirrhosis after cardiac arrest: A retrospective-prospective nested case-control study
AASLD LiverLearning®, Megan Reinders, 144931
Assessment of Presence and Dynamic evolution of Organ Failures during Early Intensive Management by MERCIC model can guide inappropriate ‘Futile Care’ in the first week in Critically Ill Cirrhotics
AASLD LiverLearning®, RAKHI MAIWALL, 144932
Jagged1 is associated with poor prognosis of HBV-related liver cancer
AASLD LiverLearning®, Kazunori Kawaguchi, 144688
Serum Ceruloplasmin can be applied to assess liver fibrosis in chronic hepatitis B virus patients with normal or minimally raised ALT
AASLD LiverLearning®, Da-Wu Zeng, 144689
Protective effects of beta-blockers in patients with acute-on-chronic liver failure including circulatory failure requiring vasopressors
AASLD LiverLearning®, Mohammed Yaquob, 144945
Universal prophylaxis with lamivudine prevents hepatitis B reactivation in HBsAg-negative/anti-HBC positive patients undergoing rituximab-based chemotherapy for non-Hodgkin b cell lymphoma - final results
AASLD LiverLearning®, Pietro Lampertico, 144690
Etiology of chronic liver disease has no impact on the course and outcome of patients with Acute on Chronic Liver Failure
AASLD LiverLearning®, Yogesh Kumar Chawla, 144946
Plasma markers of liver cell death Keratin 18 (K18) and its caspase-cleaved fragment (cK18) are novel biomarkers to define progression of cirrhotic patients with acute decompensation to acute on chronic liver failure (ACLF) and mortality
AASLD LiverLearning®, Stewart Macdonald, 144947
Factors predictive of infections in acute decompensated cirrhosis patients may help identify infections sooner than later: value of SIRS criteria upon admission.
AASLD LiverLearning®, Sandeep Yarlagadda, 144948
Impaired Anti-HBV Vaccine Response In Non-Cirrhotic Chronic HCV Patients Is Not Overcome By Double Or Additional (4th) Dosing
AASLD LiverLearning®, Mário Pessôa, 144704
AKI In Critically Ill Cirrhotics With Severe Sepsis And Septic Shock Has Major Influence On Organ Failures And Outcomes- A Prospective Study
AASLD LiverLearning®, RAKHI MAIWALL, 144961
The level of HBV RNA in serum as a novel marker for the phase of chronic hepatitis B virus (HBV) infections
AASLD LiverLearning®, Florian van Boemmel, 144706
Chronic Outpatient Intravenous Albumin Decreases Hospitalization and Mortality in Patients with Cirrhosis and Refractory Ascites or Anasarca
AASLD LiverLearning®, Brooke Osborne, 144962
Obstetricians’ Knowledge and Practices Regarding Chronic Hepatitis B in Pregnancy
AASLD LiverLearning®, Bolin Niu, 144707
Time for a new, more inclusive endpoint for treatment of type 1 hepatorenal syndrome (HRS-1)? Small changes in serum creatinine (SCr) of >20% are equivalent to HRS reversal (HRSR) in predicting survival and need for renal replacement therapy (RRT) during
AASLD LiverLearning®, Thomas Boyer, 144963
Nearly One Third of Asian Adults with Treatment Naïve Chronic Hepatitis B Virus (HBV) Infection with Elevated HBV DNA and Normal Alanine Aminotransferase Have Significant Hepatic Fibrosis
AASLD LiverLearning®, Robert Wong, 144721
Bacterascites is associated with poor clinical outcome in decompensated cirrhosis.
AASLD LiverLearning®, Rosalie Oey, 144977
Profiling Changes in Neutrophil-Lymphocyte Ratio in Response to Antiviral Therapy for Chronic Hepatitis B Infection
AASLD LiverLearning®, Marnonette Marallag, 144722
Renal replacement therapy in acute on chronic liver failure - Outcomes and predictors of survival
AASLD LiverLearning®, Suman Nayak, 144978
Proportion of Pre-Core Mutation Determines HBV Phenotype after HBeAg Seroconversion
AASLD LiverLearning®, Daniel Suarez, 144723
Predicting mortality utilizing MELD and MELD-Na after Transjugular Intrahepatic Portosystemic Shunt
AASLD LiverLearning®, Faruq Pradhan, 144979
Exploring Optimal Dosing Of Lonafarnib With Ritonavir For The Treatment Of Chronic Delta Hepatitis—Interim Results From The Lowr Hdv-2 Study.
AASLD LiverLearning®, Cihan Yurdaydin, 144737
Pulse Shaping for Improved Diagnosis of Portal Hypertension Using Subharmonic Aided Pressure Estimation
AASLD LiverLearning®, Ipshita Gupta, 144993
Comparison of the efficacy of entecavir and tenofovir monotherapy for the treatment of treatment -naïve patients with hepatitis B virus
AASLD LiverLearning®, Young Kul Jung, 144738
The clinical candidate MTL-CEBPA leads to significant reduction in ascites and improvement in overall survival in a CCl4-induced acute liver failure model.
AASLD LiverLearning®, Vikash Reebye, 144994
High Rate of HBsAg Loss After Peginterferon Based Combination Treatment for Chronic Hepatitis B Patients: Results After 5 Years of Follow-up
AASLD LiverLearning®, Femke Stelma, 144739
Hepatic microcirculatory phenotype in aging: mildly dysfunctional in health but markedly deteriorated in chronic liver injury
AASLD LiverLearning®, Raquel Maeso Diaz, 144995
HBsAg-redirected T cells have potent antiviral activity in HBV-infected human liver chimeric mice
AASLD LiverLearning®, Robert Kruse, 144753
High Frequency of Flares in Alanine Aminotransferase (ALT) And Hepatitis B Virus (HBV) DNA During Pregnancy And Postpartum in Women With Chronic Hepatitis B (CHB) Who Discontinued Therapy Prior to or During Early Pregnancy
AASLD LiverLearning®, Christine Chang, 144754
HBV Genotype Differences in Treatment Response to TAF and TDF
AASLD LiverLearning®, Maria Buti, 144755
Durability of 3-year consolidation therapy following virologic response in chronic hepatitis B patients treated with nuclios(t)ide analogues
AASLD LiverLearning®, Kwan Sik Lee, 144768
Silibinin treatment for hepatitis D: in vitro and in vivo.
AASLD LiverLearning®, Eve-Isabelle Pecheur, 144769
Population Pharmacokinetic Analysis of Peginterferon Alfa-2a (40KD) Supports the use of Bsa-Category Based Dosing Regimen in Children with Chronic Hepatitis B: PEG-B-ACTIVE Pharmacokinetic Substudy
AASLD LiverLearning®, Celine Sarr, 144770
Characterization of host, viral, and treatment-related factors associated with antiviral efficacy of tenofovir alafenamide (TAF) and tenofovir disporoxil (TDF)
AASLD LiverLearning®, Edward Gane, 144771
In vitro and in vivo anti-HBV activities of the new cyclophilin inhibitor STG-175
AASLD LiverLearning®, Philippe Gallay, 144785
Factors associated with adherence to hepatocellular carcinoma surveillance in patients undergoing hepatitis B anti-viral therapy in Australia.
AASLD LiverLearning®, Suzanne Sheppard-Law, 144530
A novel method for accurate quantification of intra-hepatic HBV cccDNA in liver biopsy specimens and its application for predicting patient’s response to interferon-α2a therapy
AASLD LiverLearning®, Yong Liao, 144786
Clinical Impact of Hepatic Steatosis in Patients with Chronic Hepatitis B Infection on Tenofovir Therapy
AASLD LiverLearning®, Jeong Eun Song, 144787
The effect after cessation of nucleos(t)ide analog(ue)s for chronic hepatitis B virus infection patients who had serum HBsAg negative is durable
AASLD LiverLearning®, Xiang-Yong Li, 144788
The Clinical Significance of IgG4 Positive Autoimmune Hepatitis
AASLD LiverLearning®, Thomas McCarty, 144544
Clinical features and long term outcomes of Autoimmune hepatitis (AIH) and its overlap with Primary Sclerosing Cholangitis (PSC)
AASLD LiverLearning®, Guan Wee Wong, 144545
Impact of age in renal safety of medium-term treatment with Entecavir and Tenofovir in real-life in a real-world cohort: Analysis of the Spanish national chronic hepatitis B register (CIBERHEP)
AASLD LiverLearning®, David Tabernero, 144801
In Well-Controlled Autoimmune Hepatitis Treatment Withdrawal May Be Safely Accomplished without Liver Biopsy Guidance
AASLD LiverLearning®, Yilien Alonso, 144546
Time-varying Serum Gradient of Hepatitis B Surface Antigen after Cessation of Nucleos(t)ide Analogues and Risk of Off-therapy Relapse
AASLD LiverLearning®, Yao-Chun Hsu, 144802
Patients with HCV GT 1/4 infection and compensated cirrhosis, without baseline NS5A RASs, could be treated with SOF + NS5A inhibitor for 12 weeks without RBV
AASLD LiverLearning®, Slim Fourati, 144803
Factors affecting clinical trial enrollment in patients with hepatitis C virus (HCV)
AASLD LiverLearning®, Vijaya L. Rao, 144804
Aged mice exhibit a more proinflammatory and fibrogenic NASH phenotype linked to the induction of Shc and NADPH oxidase 2
AASLD LiverLearning®, Sarah Fishman, 144560
Oncostatin M plays a crucial role in liver fibrogenesis by regulating cooperation between hepatic stellate cells and macrophages
AASLD LiverLearning®, Michitaka Matsuda, 144561
Daclatasvir plus Asunaprevir for Chronic Hepatitis C Virus Genotype 1b Infection; Real Life Data in Korea
AASLD LiverLearning®, Yang Jae Yoo, 144817
Protective role of specific pathogen free microbiota in bile duct ligated and CCL4 treated mice
AASLD LiverLearning®, Sheida Moghadamrad, 144562
Efficacy and safety of sofosbuvir and ledipasvir in the treatment of elderly Japanese patients with hepatitis C genotype 1 infected.
AASLD LiverLearning®, Kenji Nagata, 144818
Efficacy and safety of sofosbuvir and daclatasvir for 8 weeks in treatment-naïve non-cirrhotic patients with chronic HCV Genotype 3 Infection
AASLD LiverLearning®, Christophe Hezode, 144819
Ribavirin plasma level is an independent predictor for sustained virologic response in difficult to treat hepatitis C-infected patients treated with direct-acting antivirals + ribavirin combination (HepNed study 002)
AASLD LiverLearning®, Faydra Lieveld, 144820
Biological significance of connective tissue growth factor and its potential as a novel therapeutic target in hepatic fibrosis
AASLD LiverLearning®, Yuki Makino, 144576
Phenotype of human intrahepatic innate lymphoid cell subsets in health and disease
AASLD LiverLearning®, Ye Htun Oo, 144577
Efficacy and safety of sofosbuvir-based therapies for cirrhotic and/or elder patients with hepatitis C virus in Japan
AASLD LiverLearning®, Akihiro Tamori, 144833
Toll like receptor 4 mediates an immunosuppressive effect of hepatic stellate cells during hepatocellular carcinogenesis
AASLD LiverLearning®, Jinsheng Guo, 144578
HCV therapy selector webapp: an uniquely simple tool for evidence-based therapy selection for patients with chronic hepatitis C virus infection
AASLD LiverLearning®, Raoel Maan, 144834
Multi-center experience using Sofosbuvir & Ribavirin with and without pegylated interferon to treat hepatitis C patients with and without liver cirrhosis (RESiP Study: Real-life Experience with Sofosbuvir in Pakistan)
AASLD LiverLearning®, Javed Farooqi, 144835
Virological failures to direct acting antivirals (DAA) regimens in a real life setting show frequent resistance associated variants and may require re-treatment with unconventional strategies
AASLD LiverLearning®, Francesca Ceccherini-Silberstein, 144836
Ganglioside GD3 acetylation contributes to hepatic stellate cell activation
AASLD LiverLearning®, Carmen Vallejo, 144592
LPS aggravates fibrosis only in the early onset but not in the end stage of liver fibrosis
AASLD LiverLearning®, Suriguga S, 144593
The utilization of 8 weeks of sofosbuvir/ledipasvir single-tablet direct-acting antiviral regimen amongst the population indicated for the treatment in the United States
AASLD LiverLearning®, Sabina Heinz, 144849
Downregulated A-Kinase Anchoring Protein 12 (AKAP12) in Sinusoidal Endothelium is Associated with Vascular Changes in Hepatic Fibrogenesis of Various Etiologies
AASLD LiverLearning®, Hye Shin Lee, 144594
Prevalence and Factors Associated with Genotypic Resistance-Associated Variants of HCV Genotype 1 in Ledipasvir/Sofosbuvir Relapsers - A Multicenter Study.
AASLD LiverLearning®, Omar Mousa, 144850
Glomerular Filtration Rate Change During HCV with Sofosbuvir/Ledipasvir in HCV/HIV Coinfected Patients Treated with Tenofovir ± Boosted Protease Inhibitor
AASLD LiverLearning®, Cristina Soeiro, 144851
Quality of life of HCV patients treated with new direct-acting antiviral agents decreases during the first week of treatment and is inversely correlated with HCV viral load: a single-center prospective study
AASLD LiverLearning®, Christophe Renou, 144852
A competency-based medical education pilot for training and certification in gastroenterology and transplant hepatology
AASLD LiverLearning®, Sheela Reddy, 144608
Attention to “Cirrhosis” in the News Media in 36 Countries Worldwide: Insufficient Awareness of Non-alcoholic Compared to Alcoholic Liver Disease.
AASLD LiverLearning®, Nambi Ndugga, 144609
Exposure to sofosbuvir and daclatasvir is unchanged in liver transplant patients on cyclosporine or tacrolimus based immunosuppression
AASLD LiverLearning®, Lauriane Goldwirt, 144865
Cost-effectiveness of an HCV screening and treatment linkage intervention in US methadone maintenance treatment (MMT) programs
AASLD LiverLearning®, Benjamin Linas, 144610
Response to Direct Acting Antivirals in African American Liver and Kidney Transplant Recipients with Genotype 1 Hepatitis C Infection
AASLD LiverLearning®, Heather Snyder, 144866
Ledipasvir-Sofosbuvir for the treatment of Hepatitis C Virus Genotype 1 and 4 Post Renal Transplantation
AASLD LiverLearning®, Faisal Abaalkhail, 144867
Impact of HCV Therapy with Direct-Acting Antivirals on Lipid Profiles
AASLD LiverLearning®, Pooja Dharwadkar, 144868
The Northwell Health Real World Experience : A novel team approach is successful in overcoming barriers of access to obtaining HCV direct acting anti-viral therapies and obtaining SVR rates of 97%
AASLD LiverLearning®, Susan Lee, 144624
Improving HCV Testing in Alignment with Current Guidelines: Technology Alone is Not the Answer
AASLD LiverLearning®, Sara Miller, 144625
High efficacy of ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin for 12 weeks in treatment of genotype 1b HCV infected cirrhotic patients: a large real world cohort
AASLD LiverLearning®, Irina Girleanu, 144881
Mortality from Multidrug Resistant Colonization or Infection in Hospitalized Patients with Cirrhosis
AASLD LiverLearning®, Monica Schmidt, 144626
Sofosbuvir + simeprevir +/- ribavirin treatment is efficient in genotype 4 chronic hepatitis C patients: results of a large international cohort
AASLD LiverLearning®, Christophe Moreno, 144882
Effectiveness of Sofosbuvir/Ledipasvir and Sofosbuvir/Simeprevir for the Treatment of Hepatitis C Genotype-1: Real World Analysis
AASLD LiverLearning®, Anita Kohli, 144883
Efficacy of All-Oral HCV Therapy in People Who Inject Drugs (PWID)
AASLD LiverLearning®, Brian Conway, 144884